There is no denying that Australia hits above its weight class in early clinical research. With approvals depending solely on local Human Research Ethics Committees (HRECs), startup times in Australia are often reduced to just a few weeks rather than several months. Sponsors often flock to the country due to these timeline advantages, but many are now waking up to the country’s world-leading expertise in running complex first-in-human (FIH) studies.
As a result, Australia’s clinical trials sector is active across the entire development pathway, holding a substantial share of the global early-phase research base. According to the GlobalData clinical trials database, the country has 545 ongoing Phase I trials, and 457 Phase I/II trials, with activity extending across a broad range of therapeutic areas. Central nervous system (CNS) had 46 trials, while immunology and metabolic disorders also showed notable early-stage clinical activity.
This combination of volume and therapeutic complexity places a premium on the specialised infrastructure required for early-stage studies. These studies require intensive safety monitoring, collecting PK and PD measures, multiple routes of administration and ready access to specialist medical services, making additional purpose-built capacity a valuable addition to Australia’s clinical research landscape. In Sydney, that capacity has now expanded.
New Phase I clinical trial capacity in Sydney
To help meet this demand, Nucleus Network, a global leader in early-phase clinical trials, has opened a new facility at the North Shore Health Hub in St Leonards, Sydney. The early-phase clinical trials facility opened in September 2026, adding another specialist Phase I site to Nucleus Network’s existing Australian footprint and helping sponsors to access more beds and achieve improved scheduling flexibility.
The unit has started operating with 41 Phase I beds, with scope to extend to 70 beds across multiple wards. Nucleus Network describes the site as Australia’s newest purpose-built Phase I unit, designed for complex early-phase and FIH studies involving healthy volunteers and patients.
Planned capabilities at the unit cover FIH, drug-drug interaction, ethnopharmacology, biosimilars, thorough QT and vaccine clinical trials. The facility has also been designed to accommodate oral, intradermal, transdermal, intravenous, inhaled and subcutaneous administration. This additional capacity will help reduce bottlenecks and support sponsors looking to move early-phase programmes forward efficiently.
The Sydney site is a significant step in the growth strategy for Nucleus Network and adds another Australian location to the company’s existing presence in Melbourne and Brisbane, alongside international facilities in Minneapolis and London. The clinic bolsters the capability for Nucleus Network specialists to collaborate with a range of parties, including CROs, sponsors, biotech companies, and build research partnerships.
Sponsors now have the potential to run cohorts across the three Australian sites, supporting faster recruitment and parallel execution where protocol-appropriate. The breadth of this network enables sponsors to have improved flexibility when moving programmes into early clinical development, furthering its clinical trial capabilities and infrastructure.
The facility was officially opened on 9 October, with a ribbon-cutting ceremony conducted by Teena Pisarev – Nucleus Network CEO, Shelley Horton – Nucleus Network Brand Ambassador, James Carnegie – Chair, and Janet Moore – Executive Vice President of Operations Australia.
Those in attendance included Nucleus Network Board Representatives and shareholders Blackstone, including Jonathan Halliwell, Michael Blickstead, Matt Edstein. The event was also attended by members of Nucleus Network’s Executive Leadership Team, valued industry partners, members of the Sydney team and broader Nucleus Network teams, as well as specially invited guests.
Early-phase experience behind the Sydney clinic
One of the facility’s central features is its location within the Royal North Shore Hospital precinct.
The location places the unit within Greater Sydney, which has a population of around 5.6 million people, according to the Australian Bureau of Statistics data cited by Nucleus Network. This combination of a major metropolitan population, purpose-built Phase I infrastructure and proximity to tertiary hospital services forms a central part of the proposition for sponsors considering Australia for early-stage development.
The site is backed by Nucleus Network’s established operating model and experienced Australian clinical and medical teams, who have run over 2,500 early phase trials over more than 30 years across Nucleus Network’s four other sites.
Dr Joseph Taylor has been appointed medical director and principal investigator of the Sydney facility. A medical oncologist, Taylor has worked as an investigator on hundreds of clinical trials. His background includes medical affairs experience at GSK, giving him experience on both the investigator and sponsor sides of clinical development.
Taylor joins a wider Australian leadership team that also includes Dr Victor Wong, director of medical operations and a principal investigator. Wong has contributed to more than 200 early-phase trials involving healthy volunteers and patients, spanning FIH, single and multiple ascending dose, food-effect, drug-drug interaction, bioavailability and bioequivalence, as well as biosimilar studies.
Associate director of clinical operations for Sydney, Mugdha Joshi brings more than 18 years of clinical research experience, including work managing complex trial logistics, global workflows and cross-functional operations.
The expanded Australian infrastructure now provides biotech and pharma clients more choice, resilience and scalability for early clinical development. Through the expansion, Nucleus Network furthers its mission to advance medicines and improve the lives of patients.
To discuss how Nucleus Network’s expanded Australian Phase I network can support your next early-phase programme, contact the team or download the whitepaper below.
